Revolutionary Nasal Spray Rejuvenates Brain and Improves Memory to Prevent Dementia
- Vashisht College of Medicine have developed a nasal spray therapy that reverses brain aging by reducing inflammation and restoring memory.
- This condition is described as a slow burn of inflammation within the brain's memory center.
- Ashok Shetty, university distinguished professor and associate director of the Institute for Regenerative Medicine, alongside senior research scientists Dr.
Researchers at the Texas A&M University Naresh K. Vashisht College of Medicine have developed a nasal spray therapy that reverses brain aging by reducing inflammation and restoring memory. According to a report released on April 14, 2026, the treatment targets the chronic inflammation associated with the aging process, which scientists refer to as neuroinflammaging
.
This condition is described as a slow burn of inflammation within the brain’s memory center. This persistent inflammation can create a brain fog that impairs the ability to think, form new memories, and adapt to new environments, while also increasing the risk of disorders such as Alzheimer’s disease.
The Mechanism and Results of the Therapy
The study was led by Dr. Ashok Shetty, university distinguished professor and associate director of the Institute for Regenerative Medicine, alongside senior research scientists Dr. Maheedhar Kodali and Dr. Madhu Leelavathi Narayana. The team found that a simple nasal spray could reverse the inflammatory tide responsible for brain aging.
The researchers observed that the administration of just two doses of the nasal spray produced significant results. The therapy dramatically reduced brain inflammation and restored the brain’s cellular power plants. These changes led to a significant improvement in memory.
The effects of the treatment occurred within weeks and were found to last for several months.
Context of Non-Invasive Brain Delivery
The Texas A&M research is part of a broader scientific effort to utilize intranasal delivery to bypass the blood-brain barrier without the need for invasive surgery. Other institutions have explored similar delivery methods for different cognitive targets.
- On July 23, 2025, Wake Forest University School of Medicine published a study in Alzheimer’s &. Dementia: Translational Research & Clinical Interventions confirming that intranasal insulin safely reaches key memory regions of the brain in older adults.
- On July 3, 2024, researchers at the University of Texas Medical Branch (UTMB) developed a nasal spray intended for the non-invasive delivery of tau therapeutic antibodies directly to the brain as a potential treatment for Alzheimer’s disease.
While the Wake Forest study focused on insulin resistance as a risk factor for Alzheimer’s and the UTMB research focused on tau antibodies, the Texas A&M study specifically addresses the reversal of aging-related inflammation and the restoration of cellular function.
Future Implications for Cognitive Therapy
For decades, neuroinflammaging was considered an inevitable part of growing older. The findings from the Texas A&M team suggest that this process may be reversible, potentially reshaping the future of therapies for age-related brain decline.
The research team is now focused on developing and scaling the therapy to move beyond the initial study phase. The goal is to transition the treatment from a laboratory finding to a scalable cognitive therapy that can address brain fog and memory loss in aging populations.